Akero Therapeutics

Akero's stock doubles as midphase MASH trial generates 'transformational' data: analyst
Fierce Biotech
Mon, 01/27/25 - 11:27 am
Akero Therapeutics
MASH
clinical trials
efruxifermin
Akero, bruised from earlier failure, soars as liver scarring improves in longer MASH trial
Fierce Biotech
Mon, 03/4/24 - 11:21 am
Akero Therapeutics
efruxifermin
MASH
NASH
NASH on the Cusp: An Emerging Market Opportunity
BioSpace
Mon, 10/23/23 - 09:53 am
NASH
Viking Therapeutics
Madrigal Pharmaceuticals
Terns Pharmaceuticals
Akero Therapeutics
Hepion Pharmaceuticals
Novo Nordisk
Galmed Pharmaceuticals
Akero's stock sinks as midphase cirrhosis fail sparks flash NASH crash
Fierce Biotech
Tue, 10/10/23 - 10:10 am
Akero Therapeutics
NASH
efruxifermin
clinical trials
Spotlight – Nash in 2023 and beyond
EP Vantage
Thu, 08/3/23 - 10:03 am
NASH
Boehringer Ingelheim
Zealand Pharma
Akero Therapeutics
Axcella Health
Eli Lilly
Pfizer
Ionis Pharmaceuticals
Cascade
AstraZeneca
Gilead Sciences
Novo Nordisk
Ascletis Pharma
MediciNova
Ex-Novartis NASH drug clears clinical test, fueling Boston's pursuit of Akero, 89bio
Fierce Biotech
Wed, 06/21/23 - 10:51 am
Boston Pharmaceuticals
NASH
Novartis
Akero Therapeutics
89Bio
BOS-580
Akero’s NASH drug combined with Ozempic cut liver fat in small study
Stat
Mon, 06/5/23 - 10:10 am
Akero Therapeutics
efruxifermin
NASH
Ozempic
89Bio Enlivened by Nash success
EP Vantage
Thu, 03/23/23 - 09:50 am
89Bio
NASH
Akero Therapeutics
pegozafermin
INTERCEPT
Madrigal Pharmaceuticals
89bio’s PhII data add to quick succession of NASH readouts as field seeks turnaround
Endpoints
Wed, 03/22/23 - 10:05 am
89Bio
NASH
clinical trials
gozafermin
Akero Therapeutics
Pfizer Makes Supportive Investment in Akero's NASH Drug
BioSpace
Thu, 06/16/22 - 10:45 pm
Akero Therapeutics
Pfizer
NASH
Analysts hail Akero's midphase NASH data as best in class
Fierce Biotech
Thu, 07/2/20 - 11:10 am
Akero Therapeutics
clinical trials
NASH
efruxifermin
Akero’s success gives a new Nash mechanism hope
EP Vantage
Thu, 04/2/20 - 11:01 am
Akero Therapeutics
NASH
AKR-001
Upcoming events – Bayer and Merck look to vericiguat, and Akero bets on Nash
EP Vantage
Sat, 01/18/20 - 07:34 pm
Bayer
Merck
vericiguat
heart failure
AKR-001
Akero Therapeutics
clinical trials
NASH
Back to business for biotech flotations
EP Vantage
Wed, 07/3/19 - 09:48 am
IPOs
BridgeBio
Turning Point Therapeutics
Stoke Therapeutics
Prevail Therapeutics
Atreca
NGM Biopharmaceuticals
Akero Therapeutics
Milestone Pharmaceuticals
Morphic Therapeutics
Karuna
Four More Through the IPO Door as Life Science Firms Raise $465M
Xconomy
Thu, 06/20/19 - 11:48 am
IPOs
Personalis
Akero Therapeutics
Prevail Therapeutics
Atreca
The Week Ahead In Biotech: Conferences, PDUFA Dates Clinical Trial Readouts And IPOs
Yahoo/Benzinga
Sun, 06/16/19 - 05:41 pm
FDA
Merck
Arqule
Affimed
BeiGene
Epizyme
MorphoSys
Theravance
Allena Pharma
Akero Therapeutics
Atreca
Dermavant Sciences
Personalis
Prevail Therapeutics
Stoke Therapeutics
IPOs
New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero
BioCentury
Mon, 05/27/19 - 11:42 pm
IPOs
BridgeBio
Dermavant
Prevail Therapeutics
Atreca
Akero Therapeutics
Upstart Akero continues its swoosh into NASH space with $70M windfall round
Endpoints
Wed, 12/12/18 - 07:01 pm
Akero Therapeutics
NASH
AKR-001